Vanesa Gutiérrez

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451

Taofeek K. Owonikoko, Keunchil Park, Ramaswamy Govindan et al. · Journal of Clinical Oncology · 2021 · 267 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study

Melissa L. Johnson, Zanete Zvirbule, Åslaug Helland et al. · Journal of Thoracic Oncology · 2021 · 156 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study

Taofeek K. Owonikoko, H.R. Kim, Ramaswamy Govindan et al. · Annals of Oncology · 2019 · 89 citations · Full text

Medicine, Oncology, Pharmacology +16

KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.

Vanesa Gregorc, María González‐Cao, Stefania Salvagni et al. · Journal of Clinical Oncology · 2024 · 26 citations

Medicine, Oncology, Pharmacology +17

Amivantamab plus lazertinib vs osimertinib in first-line <i>EGFR</i>-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.

Enriqueta Felip, Byoung Chul Cho, Vanesa Gutiérrez et al. · Journal of Clinical Oncology · 2024 · 17 citations

Medicine, Oncology, Pharmacology +14